Pascal Sati, PhD, Cedars-Sinai Medical Center, Los Angeles, CA, discusses the MS-ResearchBiomarkerS (MS-ReBS; NCT05204459) study: a large-scale investigation into the value of combining information from visual assessments, blood biomarkers, and imaging biomarkers to predict disability progression in multiple sclerosis (MS). By using multiple biomarkers, it is hoped that MS disease activity can be captured more accurately, enabling a more personalized treatment approach and prevention of future relapses. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.